<DOC>
	<DOCNO>NCT01927159</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , immunogenicity BCG-vaccinated healthy adult subject investigational vaccine develop prevention pulmonary tuberculosis .</brief_summary>
	<brief_title>Phase 1 ID93 + GLA-SE Vaccine Trial BCG-Vaccinated Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Has complete write informed consent process prior start screen evaluation 2 . Male female ≥18 year ≤50 year age time randomization 3 . Agrees stay contact study site duration study , provide update contact information necessary , current plan move study area duration study 4 . Agrees avoid elective surgery full duration study 5 . For female participant : agree avoid pregnancy 21 day prior Study Day 0 full duration study . Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must use acceptable method avoid pregnancy period . Acceptable method avoid pregnancy include sterile sexual partner , sexual abstinence ( engage sexual intercourse ) , hormonal contraceptive ( oral , injection , transdermal patch , implant ) , vaginal ring , intrauterine device ( IUD ) , combination condom diaphragm spermicide gel 6 . Has general good health , confirm medical history physical examination 7 . Has body mass index ( BMI ) 19 33 ( weight/height2 ) nomogram 8 . Had BCG vaccination least 5 year ago , document medical history presence scar 1 . Acute illness time randomization 2 . Oral temperature ≥37.5°C time randomization 3 . Clinically significant abnormal laboratory value follow screen laboratory parameter , per local laboratory normal range blood collect within 30 day prior Study Day 0 randomization follow : hemoglobin , hematocrit , absolute neutrophil count , absolute lymphocyte count , platelet count lower limit normal ( LLN ) white blood cell count upper limit normal ( ULN ) LLN ( i.e. , must within normal limit ) ALT , AST , total bilirubin , alkaline phosphatase , creatinine , blood urea nitrogen ( BUN ) ULN 4 . Evidence systemic local disease process screen urinalysis 5 . Evidence significant active infection 6 . History treatment active latent tuberculosis evidence active tuberculosis 7 . Shared residence within last year prior randomization individual antituberculosis treatment culture smear positive tuberculosis 8 . History autoimmune disease immunosuppression 9 . Used immunosuppressive medication within 42 day randomization ( inhaled topical corticosteroid permit ) 10 . Received immunoglobulin blood product within 42 day randomization 11 . Received investigational drug therapy investigational vaccine within 182 day randomization , plan participation investigational study study period 12 . Received investigational Mtb vaccine time prior randomization 13 . Received live vaccine within past 4 week kill vaccine within past 2 week prior randomization . 14 . Unable discontinue current chronic prescription drug therapy hepatotoxic toxic bone marrow kidney . 15 . History laboratory evidence immunodeficiency state include limited laboratory indication HIV1 infection 16 . History allergic disease reaction ( include allergy kanamycinrelated antibiotic , allergic reaction egg , severe eczema ) , likely exacerbate component study vaccine 17 . Previous medical history may compromise safety participant study , include limited : severe impairment pulmonary function pulmonary disease ; chronic illness sign cardiac renal failure ; suspect progressive neurological disease ; uncontrolled epilepsy 18 . Evidence chronic hepatitis ( e.g. , hepatitis B surface antigen hepatitis C antibody ) 19 . Chronic heavy ethanol intake , opinion investigator , may compromise safety participant interfere evaluation safety vaccine 20 . Cannabis smoke 3 day per week 21 . Positive urine test illicit drug ( opiate , cocaine , amphetamine ) 22 . History evidence physical examination systemic disease acute chronic illness , opinion investigator , may interfere evaluation safety immunogenicity vaccine 23 . All female participant : currently pregnant lactating/nursing ; positive urine pregnancy test screen day study injection 24 . Received tuberculin skin test within 3 month ( 90 day ) prior Study Day 0 25 . Any current medical , psychiatric , occupational , substance abuse problem , opinion investigator , make unlikely participant comply protocol may compromise safety participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>TB</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>